Company BAR1 LIFE Australian S.E.

Equities

BD1

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

End-of-day quote Australian S.E. Other stock markets			5-day change	1st Jan Change
- ^AUD	-.--%		-.--%	-.--%

04-19	INOVIQ Concludes Analytical Validation for Ovarian Cancer Blood Test	MT
04-15	Fears of Middle East Conflict Escalation Quell Appetite for Australian Shares	MT

INOVIQ Ltd is an Australia-based company. The Company is engaged in developing and commercializing exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. It operates in one segment, the research and development of cancer diagnostics. The Company has two products in market, which include hTERT ICC test and the EXO-NET Pan-Exosome. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate and other cancers. The hTERT test is an immunocytochemistry (ICC) assay registered for the detection of human telomerase reverse transcriptase (hTERT) in cytopathology samples. It is used as an adjunct to urine cytology to help resolve indeterminate cytology results and identify patients with increased risk of bladder cancer. EXO-NET is a research use only (RUO) pan-exosome capture tool for the isolation of exosomes from body fluids including plasma, urine and saliva.

AUD in Million	2022	Weight	2023	Weight	Delta
Human Telomerase Reverse Transcriptase 91.2 %	0	99.0 %	0	91.2 %	+32.61%
Molecular Nets 8.8 %	0	1.0 %	0	8.8 %	+1,128.37%

AUD in Million	2022	Weight	2023	Weight	Delta
South Korea 60.4 %	0	1.0 %	0	60.4 %	+8,350.67%
United States 39.6 %	0	99.0 %	0	39.6 %	-42.49%

Managers	Title	Age	Since
Leearne Hinch CEO	Chief Executive Officer	-	16-11-06
Mark Edwards DFI	Director of Finance/CFO	-	22-11-01
Gregory Rice CTO	Chief Tech/Sci/R&D Officer	-	21-09-19

Members of the board	Title	Age	Since
David John Williams CHM	Chairman	70	11-28
Philip Powell BRD	Director/Board Member	65	19-06-17
Geoff Cumming BRD	Director/Board Member	-	20-07-27
Robert Johnston BRD	Director/Board Member	-	19-06-17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	92,018,702	65,958,065 ( 71.68 %)	0	71.68 %

Name	Equities	%	Valuation
Merchant Funds Management Pty Ltd. 14.22 %	13,082,057	14.22 %	4 M $
David John Williams 5.311 %	4,886,671	5.311 %	2 M $
Irmgard Irminger-Finger 4.163 %	3,830,756	4.163 %	1 M $
Lesamourai Pty Ltd. 1.701 %	1,565,000	1.701 %	508 124 $
Traoj Pty Ltd. 1.199 %	1,102,933	1.199 %	358 100 $
Supergun Pty Ltd. 1.108 %	1,020,000	1.108 %	331 174 $
Nathan Ryan Wagner 1.098 %	1,010,433	1.098 %	328 067 $
David Neate 0.9805 %	902,257	0.9805 %	292 945 $
Peter Cook 0.9781 %	900,000	0.9781 %	292 212 $
Trovex Pty Ltd. 0.8911 %	820,000	0.8911 %	266 238 $

INOVIQ Ltd.

23 Normanby Road

3168, Notting Hill

+61 3 9548 7586

http://www.inoviq.com

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+29.77%	49.18B
IQVIA HOLDINGS INC.	+1.00%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.71B
BIO-TECHNE CORPORATION	+8.22%	13.26B
MEDPACE HOLDINGS, INC.	+32.41%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.99B

Other Biotechnology & Medical Research